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OBJECTIVES We sought to directly compare primary stenting with accelerated tissue plasminogen activator
(t-PA) in patients presenting with acute ST-elevation myocardial infarction (AMI).
BACKGROUND Thrombolysis remains the standard therapy for AMI. However, at some institutions primary
angioplasty is favored. Randomized trials have shown that primary angioplasty is equal or
superior to thrombolysis, while recent studies demonstrate that stent implantation improves
the results of primary angioplasty.
METHODS Patients presenting with AMI were randomly assigned to primary stenting (n 5 62) or
accelerated t-PA (n 5 61). The primary end point was the composite of death, reinfarction,
stroke or repeat target vessel revascularization (TVR) for ischemia at six months.
RESULTS The primary end point was significantly reduced in the stent group compared with the
accelerated t-PA group, 24.2% versus 55.7% (p , 0.001). The event rates for other outcomes
in the stent group versus the t-PA group were as follows: mortality: 4.8% versus 3.3% (p 5
1.00); reinfarction: 6.5% versus 16.4% (p 5 0.096); stroke: 1.6% versus 4.9% (p 5 0.36);
recurrent unstable ischemia: 9.7% versus 26.2% (p 5 0.03) and repeat TVR for ischemia:
14.5% versus 49.2% (p , 0.001). The median length of the initial hospitalization was four
days in the stent group and seven days in the t-PA group (p , 0.001).
CONCLUSIONS Compared with accelerated t-PA, primary stenting reduces death, reinfarction, stroke or
repeat TVR for ischemia. In centers where facilities and experienced interventionists are
available, primary stenting offers an attractive alternative to thrombolysis. (J Am Coll Cardiol
2001;37:985–91) © 2001 by the American College of Cardiology
Thrombolysis improves survival in acute ST-segment ele-
vation myocardial infarction (AMI) (1,2). No other throm-
bolytic regimen has surpassed the survival benefit associated
with accelerated tissue plasminogen activator (t-PA) (3–5).
Several studies have found revascularization by primary
percutaneous transluminal coronary angioplasty (PTCA) to
be equal or superior to revascularization by thrombolysis
(6–12). The largest of these compared primary PTCA with
accelerated t-PA and found that PTCA reduced the com-
posite of death, reinfarction or stroke at 30 days but failed to
do so at six months (8). Primary stenting has clinical
benefits beyond those of primary PTCA (13–17) but, as yet,
has not been directly compared with thrombolysis. The
objective of this study was, therefore, to directly compare
primary stenting with accelerated t-PA.
METHODS
Patient selection. The study was conducted at the Univer-
sity of Ottawa Heart Institute, a tertiary center where
.1,200 angioplasties are performed per year. Potentially
eligible were patients presenting with AMI defined as: 1)
ischemic chest pain of $30 min duration within the
previous 12 h and 2) ST-segment elevation $1 mm
(0.1 mV) in $2 contiguous electrocardiographic leads or left
bundle branch block (LBBB) not known to be old. Patients
with any of the following were excluded: cardiogenic shock,
active bleeding, history of stroke, major surgery or trauma
within three months, systolic blood pressure $200 mm Hg
or diastolic blood pressure $120 mm Hg, cardiopulmonary
resuscitation .10 min, inadequate vascular access, PTCA
within the preceding six months, previous stenting of the
presumed infarct-related artery (IRA), previous coronary
bypass surgery (CABG), international normalized ratio
.2.0, platelet count ,100,000/mm3, hematocrit ,30%,
creatinine .300 mmol/l, intolerance to aspirin, other med-
ical condition likely to result in death within 12 months,
participation in another study within the past four weeks,
pregnancy or inability to provide informed consent. The
protocol was approved by a duly constituted Institutional
Review Board.
Study design. Each patient immediately received 160 mg
of chewable aspirin. After informed consent was obtained,
candidates were randomized to primary stenting or throm-
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bolysis. Patients were randomized in blocks of 10 using
sealed opaque envelopes.
Coronary angiography was performed as soon as possible
on patients randomized to stenting. Percutaneous translu-
minal coronary angioplasty alone was performed if the
intraluminal diameter of the IRA was ,2.5 mm or if
technical difficulties could prevent delivery or expansion of a
stent. Surgical treatment was recommended if angiography
identified: 1) left main stenosis .50% or 2) Thrombolysis
In Myocardial Infarction (TIMI) flow grade 3 in the IRA
and $70% stenosis of all three major epicardial vessels or
3) mechanical complications of AMI, such as papillary
muscle or ventricular septal rupture. Medical therapy was
recommended if angiography identified diffuse disease not
amenable to revascularization or the IRA had TIMI flow
grade 3 and the culprit site had a stenosis of ,70%.
Standard techniques were used to perform PTCA. After
predilation, stenting of the IRA was performed using the
ACS Multilink stent or the ACS Multilink Rx Duet stent
(Guidant, Advanced Cardiovascular Systems, Inc., Te-
mecula, California). The routine use of abciximab was
discouraged early in the trial. When new data suggested
benefit (18,19), its use was left to the discretion of the
operator. It was recommended to stent only the IRA.
Heparin was given to maintain an activated clotting time of
$300 s during the procedure. Afterwards, heparin infusion
was not initiated, and the femoral arterial sheath was
removed within 6 h. Beginning on the day of the procedure,
all patients received aspirin (325 mg daily continued indef-
initely) and ticlopidine (250 mg twice daily for one month)
or clopidogrel (75 mg daily for one month). Warfarin was
not used routinely.
After stenting, patients free of significant arrhythmias,
heart failure or recurrent ischemia were considered for very
early discharge at 48 h with telephone follow-up at one and
seven days.
Patients randomized to thrombolysis received accelerated
t-PA and heparin as previously reported (3). Acute coronary
angiography was recommended in the presence of: 1)
unabated chest pain associated with persistent ST-segment
elevation $2 h after initiation of thrombolysis or 2) dete-
riorating hemodynamic status. Routine coronary angiogra-
phy was discouraged, and risk stratification was performed
according to published guidelines (20).
Radionuclide ventriculography was performed within
10 days of AMI to determine the left ventricular ejection
fraction. Quantitative coronary angiography was performed
on the angiograms of patients who had primary stenting.
Coronary flow was graded according to the TIMI trial
classification (21). All patients had clinical follow-up at six
weeks and at six months.
End points and definitions. The primary end point was the
six-month composite of death, reinfarction, stroke or repeat
target vessel revascularization (TVR) for ischemia. “Reinfarc-
tion” was defined as recurrent ischemic chest pain at rest lasting
$30 min and accompanied by new or recurrent ST-segment
elevation $0.1 mV in any two contiguous leads, or a new
LBBB, or re-elevation of creatine kinase to greater than twice
the upper limit of normal. If creatine kinase was measured
before it returned to the normal range, a rise of $50% above
the lowest level from the index AMI or a rise $50% above the
sample drawn at the onset of new symptoms was considered
evidence for reinfarction. Creatine kinase was not used to
define reinfarction when chest pain recurred #18 h of onset of
the index AMI. “Stroke” was defined as a focal neurological
deficit, compatible with damage in the territory of a major
cerebral artery with signs or symptoms persisting for $24 h
and was classified as hemorrhagic or nonhemorrhagic accord-
ing to the results of computerized tomography or magnetic
resonance imaging. “Repeat TVR for ischemia” was defined as
PTCA or CABG, done for failed thrombolysis, cardiogenic
shock, reinfarction, angina at rest or with minimal exertion or
ischemia on physiological testing. However, TVR initiated by
physician preference only was not counted as an end point. In
patients randomized to primary stenting, CABG done as a
primary procedure or after failed PTCA constituted an end
point. “Cardiogenic shock” was defined as a systolic blood
pressure ,80 mm Hg not responding to fluid expansion and
requiring intravenous inotropic support or intra-aortic balloon
counterpulsation. “Recurrent unstable ischemia” was defined as
recurrent chest pain at rest associated with new ST-segment or
T wave changes, hypotension or pulmonary edema. A drop in
hemoglobin of $5 gm/dL from the baseline constituted severe
bleeding.
Each component event in the primary end point, as well
as recurrent unstable ischemia, was adjudicated by a com-
mittee consisting of a chairperson and two members who
were not investigators. To minimize bias, the research nurse
coordinator masked the treatment group before providing
relevant physician and nurses’ notes, electrocardiograms and
laboratory test results to the adjudication committee. The
data safety monitoring committee consisted of external
members who reviewed the data at regular intervals.
Abbreviations and Acronyms
AMI 5 acute ST-elevation myocardial infarction
CABG 5 coronary bypass surgery
GUSTO 5 Global Use of Strategies to Open
Occluded Coronary Arteries in Acute
Coronary Syndromes trial
IRA 5 infarct-related artery
LBBB 5 left bundle branch block
PAMI 5 Primary Angioplasty in Myocardial
Infarction trial
PTCA 5 percutaneous transluminal coronary
angioplasty
STENTIM 5 STENTing In acute Myocardial
infarction trial
t-PA 5 tissue plasminogen activator
TIMI 5 Thrombolysis In Myocardial Infarction
TVR 5 target vessel revascularization
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Statistical analysis. It was expected that .75% of the
patients randomized to the stent group would receive stent
implantation. The sample size of 124 patients (62 random-
ized per group) was based on the assumption that the six
month primary end point rate would be 40% in the
thrombolytic group and 15% in the stent group, using a
two-tailed a of 0.05 and b of 0.20.
Comparison between the two groups was performed on
an intention-to-treat basis. Categorical variables were com-
pared by the chi-square method, and continuous variables
by the Student t test. The Kaplan-Meier method was used
to assess variables pertaining to time elapsed from entry to
events. The analyses were conducted with Systat version 9.
RESULTS
Patient characteristics. Enrollment began August 1997
and ended June 1999. Of the 218 patients presenting to our
hospital who met the inclusion criteria, 123 were random-
ized—62 to primary stenting and 61 to thrombolysis. The
most common reasons for exclusion were: previous CABG
(n 5 17), patient refusal (n 5 16), unavailable catheteriza-
tion facilities (n 5 12), missed enrollment (n 5 12),
previous stroke (n 5 11), bleeding problems (n 5 7) and
inability to provide consent (n 5 5).
Groups were well matched for baseline characteristics
(Table 1). All patients assigned to thrombolysis received
accelerated t-PA. In patients assigned to primary stenting,
61 (98%) had immediate angiography performed; the re-
maining patient was given t-PA because of a potential delay
in accessing the catheterization laboratory. Stents were
successfully deployed in 50 patients (81%), while PTCA
alone was performed in two patients. Four patients had
primary CABG, but none had emergency surgery after
failed PTCA. The remaining five patients were treated with
medical therapy. Abciximab was given to 12 patients
(19.4%) assigned to the stent group.
For 36 patients treated during regular operating hours, the
median interval between randomization and first balloon in-
flation was 62 min, compared with 94 min for 26 patients
treated during off hours (1800 h to 0700 h, weekends and
holidays) (p , 0.001).
In patients treated with stents, only one patient had
TIMI flow grade 3 before dilation, compared with 46 pa-
tients (92%) after stenting (Table 2). A residual diameter
stenosis ,50% was achieved in all patients. The mean
pressure for stent expansion was 14.2 6 2.3 atm. An average
of 1.3 stents was implanted per patient.
Radionuclide ventriculography was obtained in 49 pa-
tients in the stent group (79.0%) at 6.3 6 4.2 days and in
48 patients in the t-PA group (78.6%) at 6.0 6 3.5 days.
Left ventricular ejection fraction at rest in the stent group
Table 1. Baseline Characteristics of the Patients*
Characteristics
Stent Group
(n 5 62)
t-PA group
(n 5 61)
p
Value
Mean age, yr 60.9 6 12.3 60.2 6 11.3 0.78
Age .75 yr, n (%) 6 (9.7) 8 (13.1) 0.58
Male gender, n (%) 47 (75.8) 51 (83.6) 0.37
Prior hypertension, n (%) 28 (45.2) 24 (39.3) 0.59
Diabetes mellitus, n (%) 13 (21.0) 14 (23.0) 0.83
Current smoker (,2 yrs), n (%) 34 (55.7) 34 (56.7) 1.00
Dyslipidemia, n (%) 21 (33.9) 29 (47.5) 0.14
Prior infarction, n (%) 10 (16.1) 13 (21.3) 0.50
Median systolic blood pressure, mm Hg 130 (117, 154) 130 (117, 149) 0.66
Median diastolic blood pressure, mm Hg 80 (70, 95) 80 (72, 92) 0.87
Median heart rate, beats/min 74 (60, 84) 71 (60, 81) 0.68
Location of infarction, n (%)
Anterior 26 (41.9) 23 (37.7) 0.89
Inferior 33 (53.2) 35 (57.3) 0.89
Lateral 3 (4.8) 3 (4.9) 0.68
Killip class 1, n (%) 50 (80.6) 52 (85.2) 0.63
Median interval between:
Onset of symptoms and hospital arrival, min 92 (39, 150) 88 (47, 144) 0.73
Onset of symptoms and randomization, min 153 (81, 210) 125 (80, 195) 0.31
Randomization and treatment,† min 77 (58, 97) 15 (10, 21) ,0.001
*Median values are given with interquartile ranges (the 25th and 75th percentiles); †treatment 5 start of first balloon inflation
or t-PA infusion.
t-PA 5 tissue plasminogen activator.
Table 2. Angiographic Results of Primary Stenting (n 5 50)
Before
Procedure
After
Stenting
Reference vessel diameter, mm 3.12 6 0.46 3.14 6 0.42
Minimal luminal diameter, mm 0.18 6 0.27 2.89 6 0.43
Percent diameter stenosis 94 6 9 8 6 8
Acute gain, mm 2.61 6 0.75
TIMI flow grade, n (%):
0 28 (56) 0
1 13 (26) 0
2 8 (16) 4 (8)
3 1 (2) 46 (92)
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was 50.5 6 12.2, compared with 49.5 6 10.7 in the t-PA
group (p 5 0.64).
In-hospital outcome. Primary and secondary end points
are shown in Table 3. The primary end point occurred less
frequently in the stent group, 19.4% versus 47.5% (p ,
0.001). All deaths were cardiac: three in the stent group
(4.8%) and two in the t-PA group (3.3%) (p 5 1.00).
Reinfarction occurred in 4.8% of the patients in the stent
group and 8.2% in the t-PA group (p 5 0.49). One patient
in each group experienced a stroke. Repeat TVR for
ischemia was performed in 11.3% of the patients in the stent
group and 42.6% of the t-PA group (p , 0.001).
Unscheduled coronary angiography was performed in
39 patients (63.9%) in the t-PA group, compared with seven
(11.3%) in the stent group (p , 0.001) (Table 4). Seven
patients (11.5%) who had angiography for failure of throm-
bolysis had an occluded IRA and required rescue PTCA.
Cardiogenic shock developed in four patients (6.6%) in
each group. Intra-aortic balloon counterpulsation was used
in one patient (1.6%) in the stent group and in three
patients (4.9%) in the t-PA group. Severe bleeding occurred
in four patients in the stent group (6.5%) and in seven
(11.5%) in the t-PA group (p 5 0.36); blood transfusion
was required in three patients (4.9%) in the t-PA group and
in four patients (6.5%) in the stent group. Severe bleeding
was related to CABG in six patients (4.9%), gastrointestinal
bleeding in two (1.6%), catheterization puncture site in two
(1.6%) and retroperitoneal bleeding in one (0.8%). There
were no intracranial hemorrhages.
The median length of stay was four days (interquartile
range: three to seven days) in the stent group and seven days
(interquartile range: 5 to 10 days) in the t-PA group (p ,
0.001). In the stent group, fifteen patients (24%) were
discharged within 48 h of admission and 26 within 72 h
(42%); in the t-PA group, none were discharged within 48 h
and five (8%) within 72 h.
Table 3. Primary and Secondary End Points
Stent Group
(n 5 62)
t-PA Group
(n 5 61)
Odds Ratio
(95% Confidence Interval)
p
Value
In-hospital
Primary end point,* n (%) 12 (19.4) 29 (47.5) 0.26 (0.12–0.59) ,0.001
Death, n (%) 3 (4.8) 2 (3.3) 1.50 (0.24–9.31) 1.00
Reinfarction, n (%) 3 (4.8) 5 (8.2) 0.57 (0.13–2.50) 0.49
Stroke, n (%) 1 (1.6) 1 (1.6) 0.99 (0.06–16.09) 1.00
Death or reinfarction or stroke, n (%) 7 (11.3) 6 (9.8) 1.17 (0.37–3.70) 1.00
Repeat TVR for ischemia, n (%) 7 (11.3) 26 (42.6) 0.17 (0.07–0.44) ,0.001
Angioplasty, n (%) 3 (4.8) 20 (33.3) 0.10 (0.03–0.37) ,0.001
Bypass surgery, n (%) 4 (6.5) 7 (11.5) 0.82 (0.17–3.90) 0.36
Recurrent unstable ischemia, n (%) 3 (4.8) 10 (16.4) 0.26 (0.07–0.99) 0.044
At Six Weeks
Primary end point,* n (%) 12 (19.4) 31 (50.8) 0.23 (0.10–0.52) ,0.001
Death, n (%) 3 (4.8) 2 (3.3) 1.50 (0.24–9.31) 1.00
Reinfarction, n (%) 3 (4.8) 8 (13.1) 0.34 (0.09–1.34) 0.13
Stroke, n (%) 1 (1.6) 2 (3.3) 0.48 (0.04–5.48) 0.62
Death or reinfarction or stroke, n (%) 7 (11.3) 10 (16.4) 0.65 (0.23–1.83) 0.45
Repeat TVR for ischemia, n (%) 7 (11.3) 26 (42.6) 0.17 (0.07–0.44) ,0.001
Angioplasty, n (%) 3 (4.8) 21 (34.4) 0.10 (0.03–0.35) ,0.001
Bypass surgery, n (%) 4 (6.5) 7 (11.5) 0.53 (0.15–1.92) 0.36
Recurrent unstable ischemia, n (%) 5 (8.1) 13 (21.3) 0.32 (0.11–0.97) 0.044
At Six Months
Primary end point,* n (%) 15 (24.2) 34 (55.7) 0.25 (0.12–0.55) ,0.001
Death, n (%) 3 (4.8) 2 (3.3) 1.50 (0.24–9.31) 1.00
Reinfarction, n (%) 4 (6.5) 10 (16.4) 0.35 (0.10–1.20) 0.096
Stroke, n (%) 1 (1.6) 3 (4.9) 0.32 (0.03–3.14) 0.36
Death or reinfarction or stroke, n (%) 8 (12.9) 13 (21.3) 0.55 (0.21–1.43) 0.24
Repeat TVR for ischemia, n (%) 9 (14.5) 30 (49.2) 0.18 (0.07–0.42) ,0.001
Angioplasty, n (%) 5 (8.1) 24 (39.3) 0.14 (0.05–0.41) ,0.001
Bypass surgery, n (%) 5 (8.1) 10 (16.4) 0.45 (0.14–1.40) 0.18
Recurrent unstable ischemia, n (%) 6 (9.7) 16 (26.2) 0.31 (0.11–0.88) 0.019
*Death, reinfarction, stroke or repeat target vessel revascularization for ischemia.
t-PA 5 tissue plasminogen activator; TVR 5 target vessel revascularization.
Table 4. Indications for Unscheduled Angiograms During Index
Hospitalization
Stent Group
(n 5 62)
t-PA Group
(n 5 61)
Failure of thrombolysis NA 7 (11.5%)
Cardiogenic shock 0 3 (4.9%)
Reinfarction 3 (4.8%) 3 (4.9%)
Angina at rest 0 13 (21.3%)
Physiological testing 0 6 (9.8%)
Pulmonary edema 1 (1.6%) 0 (%)
Physician preference 3 (4.8%) 7 (11.5%)
Total 7 (11.3%) 39 (63.9%)
t-PA 5 tissue plasminogen activator.
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Discharge to six weeks. None of the patients in the stent
group experienced death, reinfarction, stroke or TVR for
ischemia between discharge and six weeks. However, events
continued to accrue in the t-PA group (Table 3).
Follow-up at six months. The primary end point was
reduced in the stent group: 24.2% versus 55.7% (p , 0.001)
(Fig. 1). This difference is largely explained by the lower rate
of repeat TVR for ischemia in the stent group: 14.5% versus
49.2% (p , 0.001) (Table 3). Among the 50 patients treated
with primary stenting, 10.0% required repeat TVR. No
other deaths ensued from discharge to follow-up. All
strokes were nonhemorrhagic. By six months, recurrent
unstable ischemia occurred less frequently in the stent
group: 9.7% versus 26.2% (p 5 0.019). The composite of
death, stroke reinfarction or recurrent unstable ischemia was
also lower in the stent group: 16.1% compared with 32.8%
in patients assigned to the t-PA group (p 5 0.032) (Fig. 2).
There were no primary or secondary events in the
26 patients discharged within 72 h after randomization to
primary stenting. At discharge, lipid-lowering medications
were prescribed less frequently in the stent group (p 5
0.02), while nitrates (p 5 0.03) and ticlopidine (p , 0.001)
were prescribed more frequently. However, at six months
after enrollment, there was no difference between the two
groups in the cardiac medications prescribed (Table 5).
DISCUSSION
Compared with thrombolysis, primary stenting was associ-
ated with a significant reduction in the combined end point
of death, reinfarction, stroke or repeat TVR for ischemia at
six months, as well as in recurrent unstable ischemia. The
median length of initial hospitalization was also reduced in
the stent group, suggesting that the costs associated with
primary stenting may be offset by reductions in the need for
subsequent care.
Several trials have compared PTCA with thrombolysis
for AMI (6–8,10–12,22,23). Percutaneous transluminal
coronary angioplasty versus streptokinase improves survival
over five years (12) and versus standard t-PA reduces death
or reinfarction in-hospital (6) and at two years (11). These
benefits may not have been evident if accelerated t-PA had
been used instead. The Global Use of Strategies to Open
Occluded Coronary Arteries in Acute Coronary Syndromes
(GUSTO) IIb trial reported that PTCA compared with
accelerated t-PA reduces death, reinfarction or stroke at
30 days but not at six months (8). The loss of benefit was
attributed to reocclusion after PTCA (8), which occurs in
10% to 15% of patients within six months (24,25).
Stent implantation in the IRA is feasible, safe and a
useful adjunct to primary PTCA (13–17,26,27). Stenting
leads to a large intraluminal gain. This may produce a more
rapid and complete restoration of flow in the IRA, an
important determinant of survival (1,3,28).
Five randomized trials have shown that primary stenting
provides clinical benefits beyond those of primary PTCA
(13–17). In three of these trials, randomization was performed
only after the guidewire crossed the occlusion (14,15) or after
successful balloon dilation was performed (13). The Stent
Primary Angioplasty in Myocardial Infarction (PAMI) study
(16) and the STENTing In acute Myocardial infarction
(STENTIM) 2 study (17) randomized patients after angiog-
raphy, thus avoiding a bias toward more favorable lesions.
Primary stenting reduced the six-month composite of death,
reinfarction, stroke or repeat TVR for ischemia in Stent-
PAMI and was associated with a trend towards fewer clinical
events in STENTIM-2; angiographic restenosis was lower
with primary stenting in both studies. Still, the clinical benefit
obtained by stenting may not have been fully appreciated,
because 15% of the patients assigned to PTCA in Stent-
PAMI and 36% in STENTIM-2 crossed over to stenting.
Patients undergoing primary stenting in this study had similar
initial angiographic results and subsequent rates of repeat TVR
for ischemia as reported in Stent-PAMI and STENTIM-2.
Because our study randomized patients in the emergency room
before angiography and showed stenting to be feasible in a
high percentage of patients, the results may be more directly
applicable to clinical decisions regarding the optimal strategy in
AMI.
Some believe that primary stenting puts excessive strain
on available resources. However, angiograms were per-
formed during initial hospitalization in 63.9% of patients
Figure 2. Kaplan-Meier curves for freedom from death, reinfarction,
stroke or recurrent unstable ischemia within 180 days after randomization
according to treatment group. t-PA 5 tissue-plasminogen activator.
Figure 1. Kaplan-Meier curves for freedom from the primary end point—
death, reinfarction, stroke or repeat target vessel revascularization for
ischemia within 180 days after randomization according to treatment
group. t-PA 5 tissue plasminogen activator.
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randomized to t-PA and rescue PTCA in 11.5%, rates
similar to previous reports (8). Treatment with accelerated
t-PA mandates intravenous heparin for $48 h after initi-
ating therapy, and subsequent risk stratification after throm-
bolysis may further extend the length of hospitalization. In
our study, 24% of the patients in the stent group were
discharged within 48 h of admission and 42% within 72 h.
This resulted in a reduced median length of hospitalization
in the stent group (6).
Abciximab reduces urgent TVR after primary PTCA
(18). Recently, the effect of primary stenting plus abciximab
was compared with t-PA in 140 patients (29). Improved
myocardial salvage and a better clinical outcome were
obtained in the group that received stent with abciximab.
The composite of death, reinfarction or stroke at six months
was lower in the stent group, 8.5% versus 23.2%. In our
study, platelet glycoprotein IIb/IIIa inhibitors were not used
routinely, yet the clinical outcomes were similar. The
Controlled Abciximab and Device Investigation to
Lower Late Angioplasty Complications trial (CADIL-
LAC) will determine if abciximab provides additional
clinical benefit to primary angioplasty with and without
stent implantation.
Study limitations. Because of its small sample size, our
study was not powered to address the effect of primary
stenting on mortality or reinfarction. Although there was a
trend towards less reinfarction in the stent group, repeat
TVR for ischemia was predominantly responsible for the
reduction in the primary outcome in the stent group. The
composite of death, stroke, reinfarction and recurrent un-
stable ischemia was also lower in the stent group. Our
results are, therefore, clinically important.
Conclusions. The promising results on the primary out-
come, combined with the demonstrated reductions in re-
current unstable ischemia, repeat TVR for ischemia and
length of hospitalization suggest that primary stenting is a
very attractive alternative to thrombolysis. Larger random-
ized trials, and studies evaluating the cost-effectiveness of
primary stenting, will define its role in AMI.
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